Literature DB >> 31737537

Variant panorama in 1,385 index patients and sensitivity of expanded next-generation sequencing panels in arrhythmogenic disorders.

Christoph Marschall1, Alexander Moscu-Gregor1, Hanns-Georg Klein1.   

Abstract

BACKGROUND: Arrhythmogenic disorders occur in a broad spectrum of cardiac pathologies in the general population with a prevalence of 1:10,000 to 1:500. Genetic studies conducted during the past 20 years have markedly illuminated the genetic basis of inherited cardiac disorders. However, uncertainty exists regarding which genes should be included and routinely assessed on genetic testing panels. Here, we review the genetic basis of the most important arrhythmogenic disorders found in our laboratory since 2016 by next-generation sequencing (NGS) analysis.
METHODS: We analyzed sequence data from 1,385 clinical index cases with a suspected diagnosis of long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), hypertrophic cardiomyopathy (HCM), dilatative cardiomyopathy (DCM) or arrhythmogenic right ventricular cardiomyopathy (ARVC). Genetic testing was performed by NGS using a custom design based on an Agilent SureSelectQXT.
RESULTS: The detection rate of pathogenic or likely pathogenic variants was in the range of 16% for BrS to 40% for HCM. Only the few well known core genes and some additional side genes substantially contribute to the diagnostic sensitivity.
CONCLUSIONS: Clinical testing provides a definitive diagnosis for many patients. The genetic result may be important for risk stratification, genetic counseling and, in some cases, treatment planning. Diagnostic panels should not be further expanded as inclusion of many genes rather produces variants of unclear significance and confusing reports. 2019 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Brugada; Genes; cardiomyopathy; genetic testing; long QT; next-generation sequencing (NGS)

Year:  2019        PMID: 31737537      PMCID: PMC6837920          DOI: 10.21037/cdt.2019.06.06

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  20 in total

Review 1.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 2.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture.

Authors:  Ray E Hershberger; Dale J Hedges; Ana Morales
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

3.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Philippe Charron; Michael Arad; Eloisa Arbustini; Cristina Basso; Zofia Bilinska; Perry Elliott; Tiina Helio; Andre Keren; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Andreas Perrot; Claudio Rapezzi; Arsen Ristic; Hubert Seggewiss; Irene van Langen; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2010-09-07       Impact factor: 29.983

4.  High-throughput genetic characterization of a cohort of Brugada syndrome patients.

Authors:  Chiara Di Resta; Alessandro Pietrelli; Simone Sala; Paolo Della Bella; Gianluca De Bellis; Maurizio Ferrari; Roberta Bordoni; Sara Benedetti
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

5.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

6.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples.

Authors:  Roddy Walsh; Kate L Thomson; James S Ware; Birgit H Funke; Jessica Woodley; Karen J McGuire; Francesco Mazzarotto; Edward Blair; Anneke Seller; Jenny C Taylor; Eric V Minikel; Daniel G MacArthur; Martin Farrall; Stuart A Cook; Hugh Watkins
Journal:  Genet Med       Date:  2016-08-17       Impact factor: 8.822

7.  TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT.

Authors:  Harsha D Devalla; Roselle Gélinas; Elhadi H Aburawi; Abdelaziz Beqqali; Philippe Goyette; Christian Freund; Marie-A Chaix; Rafik Tadros; Hui Jiang; Antony Le Béchec; Jantine J Monshouwer-Kloots; Tom Zwetsloot; Georgios Kosmidis; Frédéric Latour; Azadeh Alikashani; Maaike Hoekstra; Jurg Schlaepfer; Christine L Mummery; Brian Stevenson; Zoltan Kutalik; Antoine Af de Vries; Léna Rivard; Arthur Am Wilde; Mario Talajic; Arie O Verkerk; Lihadh Al-Gazali; John D Rioux; Zahurul A Bhuiyan; Robert Passier
Journal:  EMBO Mol Med       Date:  2016-12-01       Impact factor: 12.137

8.  Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome.

Authors:  S Mohsen Hosseini; Raymond Kim; Sharmila Udupa; Gregory Costain; Rebekah Jobling; Eriskay Liston; Seema M Jamal; Marta Szybowska; Chantal F Morel; Sarah Bowdin; John Garcia; Melanie Care; Amy C Sturm; Valeria Novelli; Michael J Ackerman; James S Ware; Ray E Hershberger; Arthur A M Wilde; Michael H Gollob
Journal:  Circulation       Date:  2018-09-18       Impact factor: 29.690

9.  Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation.

Authors:  Gustav Ahlberg; Lena Refsgaard; Pia R Lundegaard; Laura Andreasen; Mattis F Ranthe; Nora Linscheid; Jonas B Nielsen; Mads Melbye; Stig Haunsø; Ahmad Sajadieh; Lu Camp; Søren-Peter Olesen; Simon Rasmussen; Alicia Lundby; Patrick T Ellinor; Anders G Holst; Jesper H Svendsen; Morten S Olesen
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

10.  Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center.

Authors:  Francesco Mazzarotto; Francesca Girolami; Roddy Walsh; Iacopo Olivotto; Beatrice Boschi; Fausto Barlocco; Alessia Tomberli; Katia Baldini; Raffaele Coppini; Ilaria Tanini; Sara Bardi; Elisa Contini; Franco Cecchi; Elisabetta Pelo; Stuart A Cook; Elisabetta Cerbai; Corrado Poggesi; Francesca Torricelli
Journal:  Genet Med       Date:  2018-06-06       Impact factor: 8.822

View more
  3 in total

1.  Eosinophilic Infiltration of the Sino-Atrial Node in Sudden Cardiac Death Caused by Long QT Syndrome.

Authors:  Simone Grassi; Oscar Campuzano; Mònica Coll; Francesca Cazzato; Anna Iglesias; Francesco Ausania; Francesca Scarnicci; Georgia Sarquella-Brugada; Josep Brugada; Vincenzo Arena; Antonio Oliva; Ramon Brugada
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

2.  The Combined Human Genotype of Truncating TTN and RBM20 Mutations Is Associated with Severe and Early Onset of Dilated Cardiomyopathy.

Authors:  Anna Gaertner; Julia Bloebaum; Andreas Brodehl; Baerbel Klauke; Katharina Sielemann; Astrid Kassner; Henrik Fox; Michiel Morshuis; Jens Tiesmeier; Uwe Schulz; Ralph Knoell; Jan Gummert; Hendrik Milting
Journal:  Genes (Basel)       Date:  2021-06-08       Impact factor: 4.096

Review 3.  Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation.

Authors:  Oscar Campuzano; Georgia Sarquella-Brugada; Elena Arbelo; Sergi Cesar; Paloma Jordà; Alexandra Pérez-Serra; Rocío Toro; Josep Brugada; Ramon Brugada
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.